Inicio › Carcinoma urotelial (de células de transición) › Nueva York

Ensayos clínicos de Carcinoma urotelial (de células de transición) en Nueva York

29 estudios sobre Carcinoma urotelial (de células de transición) buscan participantes en Nueva York.

Ciudades en Nueva York

Texto oficial del estudio (inglés)

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Roswell Park Cancer Institute, Buffalo
Stony Brook University Medical Center, Stony Brook
Roswell Park Amherst Center, Williamsville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT06524544

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

START New York Long Island LLC, Lake Success

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #60, New York
Exelixis Clinical Site #6, New York
Exelixis Clinical Site #76, Syracuse

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT05176483

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
y 3 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT03866382

DBC-664 in Adult Patients With Solid Tumors

START New York, Lake Success

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07705035

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

The Feinstein Institutes for Medical Research, Lake Success
NYU Grossman School of Medicine, New York
SUNY Upstate, Syracuse

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05874921

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Memorial Sloan Kettering Cancer Center ( Site 1031), New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05562830

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

New York Oncology Hematology, Albany
New York Oncology Hematology, Clifton Park
Icahn School of Medicine at Mount Sinai, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07421700

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Columbia University Irving Medical Center, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07277413

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College, New York
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07218380

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Mount Sinai Hospital, New York
NYP/Weill Cornell Medical Center, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT06439836

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Memorial Sloan Kettering -Nassau, Commack
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Cancer Center, New York
y 1 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT05239624

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
y 1 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07532902

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
Columbia University, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT04977453

A Study of GEN1106 in Participants With Solid Tumors

START New York Long Island LLC, Lake Success

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT07416123

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06293898

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

University of Rochester Medical Center, Rochester
Montefiore Medical Center - Bronx, The Bronx

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06774131

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

START New York Long Island, New Hyde Park

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07287995

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

New York Cancer & Blood Specialists, New York
University of Rochester - Wilmot Cancer Institute, Rochester

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT06582017

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NYU Langone Health, New York
Icahn School of Medicine At Mount Sinai Prime, New York
Clinical Research Alliance, Inc, Westbury
y 1 más

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06330064

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

MSK Commack, Commack
MSK Wesrchester, Harrison
Memorial Sloan Kattering Cancer Centre- Investigational Drug Service Pharmacy, Long Island City
y 6 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT04879329

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Research Site, Albany
Research Site, New York

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT07720284

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT06695845

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Albany MED Health System, Albany
Integrated Medical Professionals, New York
Premier Medical Group of the Hudson Valley, P. C., Poughkeepsie

Reclutando

Edades de 18 a 88 · Todos los sexos · Actualizado el 2 jul 2026 · NCT06394869

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Start New York, LLC, Lake Success
MSK, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 jun 2026 · NCT07484022

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
y 1 más

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 may 2026 · NCT07390617

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
y 1 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 abr 2026 · NCT05562791

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Site 02-015 - Associated Medical Professionals of New York, Syracuse

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 nov 2025 · NCT03945162

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Buffalo
Massive Bio SYNERGY-AI site, Hempstead
Massive Bio SYNERGY-AI site, Manhasset
y 2 más

ReclutandoEstudio observacional

Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774

De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.